Evidence map›Paper›PMID 41448440›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2026

Inhalable perfluorocarbon RNA nanocapsules overcome biological barriers to treat lung metastases.

Kasturi Siddhanta, Neha Kumari, Aditya Sundar, Atefehsadat Monirvaghefi, Braeden R Pinkerton, Ling Ding, C J Woslager, Marjina Akter Kalpana, Chinmay M Jogdeo, Ashley R Ravnholdt and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kasturi SiddhantaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA; Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Neha KumariDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA; Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Aditya SundarMaterials Science Division, Argonne National Laboratory, 9700 S. Cass Avenue, Lemont, IL 60439, USA.
Atefehsadat MonirvaghefiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Braeden R PinkertonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA; Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Ling DingDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA; Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, NE 68198, USA.
C J WoslagerDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Marjina Akter KalpanaDepartment of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Chinmay M JogdeoDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Ashley R RavnholdtDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Jill A PooleDivision of Allergy & Immunology, University of Nebraska Medical Center, Omaha, NE, USA.
Joshua L SantarpiaDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Global Center for Health Security, University of Nebraska Medical Center, Omaha, NE 68198, USA.
James E TalmadgeDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
David OupickýDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA; Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: david.oupicky@unmc.edu.

Funding

Nebraska Center for Nanomedicine- Pilot ProjectsP30GM127200 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2018 to 2022
$5.7M
Self-immolative prodrug/miRNA nanoparticle combinations for cancer treatmentR01CA235863 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CASERO, ROBERT A., OUPICKY, DAVID · 2019 to 2023
$2.3M
Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel diseaseR01DK124095 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID, SINGH, AMAR B · 2020 to 2023
$2.1M
Development of siRNA conjugates for combination treatment of acute kidney injuryR01DK120533 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID, PADANILAM, BABU JOSEPH · 2018 to 2022
$2.1M
NCI NIH HHS R01 CA235863NIDDK NIH HHS R01 DK120533NIDDK NIH HHS R01 DK124095NIGMS NIH HHS P30 GM127200
6 · The paper itself

Abstract

Inhalation RNA therapy offers to transform treatment of pulmonary diseases, yet mucus trapping, immune clearance, and navigation of heterogeneous lung tissue architecture prevents RNA from reaching its target cells. Here, we advance our previously reported perfluorocarbon (PFC) emulsion polyplex platform by developing stably aerosolized PFC-based miRNA nanocapsules. These nanocapsules are stabilized by PAMD-C, which is a cholesterol-modified polymeric analog of the FDA-approved CXCR4 antagonist AMD3100 (plerixafor). The nanocapsules exhibit negligible immune clearance, minimal inflammatory response, and efficient mucus transport, while passively homing to lung epithelial and tumor cells. After a single aerosolized dose in orthotopic lung metastasis model, more than 60 % of cancer cells and most type II alveolar and bronchial epithelial cells internalized the nanocapsules, with observed pulmonary retention exceeding 48 h. The nanocapsule provokes negligible cytokine release, enabling repeated dosing. Treatment with therapeutic miR-34a mimic suppresses metastatic outgrowth, potentiates anti-tumor immunity, and doubles median survival relative to control paclitaxel chemotherapy. By combining unique PFC disposition features with RNA versatility, the delivery platform overcomes main biological barriers for inhalable RNA medicines and opens a translatable path for treating diverse pulmonary diseases.

Indexed as

FluorocarbonsLung NeoplasmsMicroRNAsNanocapsulesAdministration, InhalationAnimalsCell Line, TumorFemaleHumansMicePaclitaxelFluorocarbonsMicroRNAsNanocapsulesPaclitaxelCancer therapyInhalable genetic medicinePerfluorocarbonRNA delivery

Identifiers

PMID41448440
PMCPMC13170091

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.